Ligand validation:5ZSN

NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose

NAG is a Ligand Of Interest in 5ZSN designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
5ZSN_NAG_A_1006	84%	48%	0.091	0.952	0.58	1.39	-	3	0	0	100%	0.9333
5ZSN_NAG_A_1001	75%	53%	0.129	0.964	0.46	1.33	-	4	1	0	100%	0.9333
5ZSN_NAG_B_1009	71%	66%	0.127	0.947	0.48	0.81	-	-	0	0	100%	0.9333
5ZSN_NAG_B_1004	70%	48%	0.128	0.944	0.49	1.5	-	3	0	0	100%	0.9333
5ZSN_NAG_B_1008	68%	38%	0.147	0.96	0.74	1.66	-	3	0	0	100%	0.9333
5ZSN_NAG_B_1006	65%	37%	0.152	0.956	0.86	1.58	-	2	0	0	100%	0.9333
5ZSN_NAG_B_1001	63%	44%	0.147	0.944	0.7	1.43	-	3	0	0	100%	0.9333
5ZSN_NAG_B_1005	49%	58%	0.192	0.939	0.48	1.11	-	2	0	0	100%	0.9333
5ZSN_NAG_B_1007	29%	44%	0.215	0.874	0.73	1.43	-	1	0	0	100%	0.9333
6IF5_NAG_A_1004	86%	28%	0.085	0.953	0.87	1.99	1	6	0	0	100%	0.9333
5ZSL_NAG_A_901	83%	53%	0.106	0.966	0.48	1.32	-	1	1	0	100%	0.9333
5GMH_NAG_A_905	82%	31%	0.101	0.957	1.02	1.7	1	4	0	0	100%	0.9333
8TTY_NAG_A_905	80%	81%	0.087	0.936	0.27	0.55	-	-	0	0	100%	0.9333
6LVZ_NAG_A_902	79%	45%	0.106	0.951	0.71	1.39	-	2	2	0	100%	0.9333
3H0C_NAG_A_794	100%	56%	0.021	0.995	0.61	1.08	-	1	0	0	100%	0.9333
5LDS_NAG_B_1007	100%	67%	0.022	0.995	0.48	0.79	-	-	0	0	100%	0.9333
5O5D_NAG_A_601	100%	65%	0.022	0.994	0.32	0.99	-	1	0	0	100%	0.9333
6MUG_NAG_G_629	100%	76%	0.022	0.994	0.35	0.58	-	-	0	0	100%	0.9333
3GXM_NAG_A_498	100%	45%	0.026	0.992	0.75	1.34	-	2	0	0	100%	0.9333

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.